Q-omics provides the consensus-scored EIF3B profile across patient tissues and cancer cell-line models. EIF3B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EIF3B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, EIF3B protein abundance shows 32,174 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where EIF3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3B survival associations across molecular data types. EIF3B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3B RNA expression–survival associations across cancer types. High EIF3B expression shows unfavorable associations in MESO, LIHC, HNSC, KICH, ACC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EIF3B RNA expression.
This table summarizes EIF3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EIF3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3B shows higher tumor expression in COAD, HNSC, KIRC, KIRP, STAD and LIHC. The COAD box plot shows higher EIF3B RNA expression in tumor versus normal tissue (log2 FC = +1.482, t-test p < 0.001).
This table shows molecular features associated with EIF3B in patient tissues and cancer cell lines. In patient samples, EIF3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
